Trials / Terminated
TerminatedNCT03225846
Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients With Huntington's Disease
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- Wave Life Sciences Ltd. · Industry
- Sex
- All
- Age
- 25 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
PRECISION-HD2 is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of WVE-120102 in adult patients with early manifest Huntington's disease (HD) who carry a targeted single nucleotide polymorphism (SNP) rs362331 (SNP2).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | WVE-120102 | WVE-120102 is a stereopure antisense oligonucleotide (ASO) |
| DRUG | Placebo | 0.9% Sodium Chloride |
Timeline
- Start date
- 2017-07-17
- Primary completion
- 2021-05-10
- Completion
- 2021-05-10
- First posted
- 2017-07-21
- Last updated
- 2022-04-25
- Results posted
- 2022-04-25
Locations
26 sites across 8 countries: United States, Australia, Canada, Denmark, France, Germany, Poland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03225846. Inclusion in this directory is not an endorsement.